Zealand planning NASDAQ listing

Metabolic company Zealand Pharma A/S (CSE:ZEAL) filed to raise up to $86.3 million via a listing of ADSs on NASDAQ underwritten by Morgan Stanley and Goldman Sachs.

Zealand's partner Sanofi (Euronext:SAN; NYSE:SNY) markets the company's lixisenatide in the U.S. as Adlyxin and in the EU as Lyxumia to treat Type II diabetes. Sanofi also markets a combination of lixisenatide plus its own Lantus insulin glargine in the U.S. as Soliqua 100/33 and in the EU as Suliqua...